Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401081 | 1.00 | CYP1A2 (0.44) | CYP1A2CYSLTR1CYSLTR2NPY5RGPBAR1 | |
| SCHEMBL9005990 | 0.84 | CYP1A2 (0.46) | CYP1A2CYSLTR1CYSLTR2GPBAR1ALDH1A1 | |
| SCHEMBL7141295 | 0.81 | PDE10A (0.37) | CYSLTR1CYSLTR2ALDH1A1MEN1KMT2A | |
| SCHEMBL17974789 | 0.80 | PDE10A (0.50) | CYP1A2NPY5RALDH1A1MAPTHPGD | |
| SCHEMBL5010543 | 0.80 | PGK1 (0.52) | NPY5RMAPTHPGD | |
| SCHEMBL3723566 | 0.79 | NCF1 (0.47) | CYP1A2ALDH1A1GAAMAPTHPGD | |
| SCHEMBL31018934 | 0.79 | NCF1 (0.47) | CYP1A2ALDH1A1GAAMAPTHPGD | |
| SCHEMBL14769225 | 0.78 | CYP1A2 (0.52) | CYP1A2CYSLTR1CYSLTR2GPBAR1ALDH1A1 | |
| SCHEMBL25308493 | 0.77 | NPC1 (0.43) | CYSLTR1CYSLTR2GPBAR1MEN1KMT2A | |
| SCHEMBL1585267 | 0.77 | CYP1A2 (0.45) | CYP1A2CYSLTR1CYSLTR2GPBAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063784-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP1A2 634/4885CYSLTR1 315/4885CYSLTR2 386/4885 |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP1A2 618/4885CYSLTR1 327/4885CYSLTR2 392/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP1A2 618/4885CYSLTR1 327/4885CYSLTR2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.